Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms22084071 http://scihub22266oqcxt.onion/10.3390/ijms22084071 33920790!8071172!33920790     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33920790&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Int+J+Mol+Sci 2021 ; 22 (8): ? Nephropedia Template TP {{tp|p=33920790|t=2021. Cardiovascular Outcomes in the Acute Phase of COVID-19 |pdf=|usr=}}{{33920790}} gab.com Text Cardiovascular Outcomes in the Acute Phase of COVID-19 JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33920790 #FOAvip The cumulative number of cases in the current global coronavirus disease 19 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exceeded 100 million, with the number of deaths caused by the infection having exceeded 2.5 million. Recent reports from most frontline researchers have revealed that SARS-CoV-2 can also cause fatal non-respiratory conditions, such as fatal cardiovascular events. One of the important mechanisms underlying the multiple organ damage that is now known to occur during the acute phase of SARS-CoV-2 infection is impairment of vascular function associated with inhibition of angiotensin-converting enzyme 2. To manage the risk of vascular dysfunction-related complications in patients with COVID-19, it would be pivotal to clearly elucidate the precise mechanisms by which SARS-CoV-2 infects endothelial cells to cause vascular dysfunction. In this review, we summarize the current state of knowledge about the mechanisms involved in the development of vascular dysfunction in the acute phase of COVID-19. Twit Text FOAVip Cardiovascular Outcomes in the Acute Phase of COVID-19 ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33920790 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33920790 #FOAvip English Wikipedia <ref>{{Cite pmid|33920790}}</ref> Cardiovascular Outcomes in the Acute Phase of COVID-19 #MMPMID33920790 Nakano H; Shiina K; Tomiyama H Int J Mol Sci 2021[Apr]; 22 (8): ? PMID33920790show ga The cumulative number of cases in the current global coronavirus disease 19 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exceeded 100 million, with the number of deaths caused by the infection having exceeded 2.5 million. Recent reports from most frontline researchers have revealed that SARS-CoV-2 can also cause fatal non-respiratory conditions, such as fatal cardiovascular events. One of the important mechanisms underlying the multiple organ damage that is now known to occur during the acute phase of SARS-CoV-2 infection is impairment of vascular function associated with inhibition of angiotensin-converting enzyme 2. To manage the risk of vascular dysfunction-related complications in patients with COVID-19, it would be pivotal to clearly elucidate the precise mechanisms by which SARS-CoV-2 infects endothelial cells to cause vascular dysfunction. In this review, we summarize the current state of knowledge about the mechanisms involved in the development of vascular dysfunction in the acute phase of COVID-19. |Acute Disease[MESH] |Angiotensin I/metabolism[MESH] |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Arteries/physiology/physiopathology[MESH] |COVID-19/*complications/*epidemiology[MESH] |Cardiovascular Diseases/*epidemiology/*etiology[MESH] |Humans[MESH] |Morbidity[MESH] |Peptide Fragments/metabolism[MESH]Cardiovascular Outcomes in the Acute Phase of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing